drugset / Trial / NCT05361954
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).
Timeline
- Start
- 2023-08
- Primary completion
- 2026-10
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-1386 | Other / unclassified | 1e+06 unknown | — |
| Subject | STI-1386 | Other / unclassified | 1e+07 unknown | — |
| Subject | STI-1386 | Other / unclassified | 1e+08 unknown | — |